ALLG MM26/D1: Novel Combinations for Orphan Myeloma: The NORM Platform study: Treatment Specific Appendix - Selinexor, Pomalidomide, Dexamethasone (SPd)
- Conditions
- Relapsed/ Refractory Multiple MyelomaCancer - Myeloma
- Registration Number
- ACTRN12622001313729
- Lead Sponsor
- Australasian Leukaemia & Lymphoma Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 140
Eligibility criteria specific to Treatment Specific Appendix - Selinexor, Pomalidomide, Dexamethasone (SPd) include:
1.Previous bortezomib therapy and either: failure to achieve at least a partial response (PR) during treatment OR progressive disease (PD) during treatment or within 6 months of discontinuing treatment OR contraindication or experienced an intolerance to treatment with bortezomib AND
2.Previous lenalidomide therapy and either: treatment failure with lenalidomide, as confirmed by progressive disease during treatment within 6 months of discontinuing lenalidomide OR a contraindication or intolerance to treatment with lenalidomide.
3.Must agree to contraceptive requirements
See ALLG MM26/NORM: Novel Combinations for Orphan Myeloma: The NORM platform study Master Protocol for eligibility criteria relevant to all domain protocols.
Exclusion criteria specific to Treatment Specific Appendix - Selinexor, Pomalidomide, Dexamethasone (SPd) include:
1.Previous treatment with pomalidomide or Selinexor
2.Contraindication to pomalidomide, Selinexor or dexamethasone
3.Active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of trial treatments.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method